Quest Partners LLC Makes New $241,000 Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Quest Partners LLC acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,729 shares of the specialty pharmaceutical company’s stock, valued at approximately $241,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SUPN. Armistice Capital LLC grew its position in shares of Supernus Pharmaceuticals by 47.6% during the second quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock worth $141,026,000 after buying an additional 1,700,000 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Supernus Pharmaceuticals by 100,186.3% in the 2nd quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company’s stock valued at $36,109,000 after purchasing an additional 1,348,508 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Supernus Pharmaceuticals by 369.1% during the 2nd quarter. American Century Companies Inc. now owns 501,658 shares of the specialty pharmaceutical company’s stock worth $13,419,000 after purchasing an additional 394,728 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Supernus Pharmaceuticals by 26.4% during the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after purchasing an additional 351,900 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Supernus Pharmaceuticals by 12.1% during the second quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after purchasing an additional 309,966 shares in the last quarter.

Insider Activity

In other news, SVP Frank Mottola sold 15,000 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the transaction, the senior vice president now directly owns 8,200 shares in the company, valued at $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jack A. Khattar sold 125,000 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the sale, the chief executive officer now owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 154,213 shares of company stock valued at $5,660,180. Company insiders own 9.30% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Trading Up 0.1 %

Shares of SUPN opened at $36.14 on Wednesday. The company’s 50 day simple moving average is $33.81 and its 200-day simple moving average is $31.14. The firm has a market cap of $2.00 billion, a PE ratio of 33.78 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. During the same period last year, the firm posted ($0.29) EPS. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% on a year-over-year basis. As a group, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.